Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Thrombotic antiphospholipid syndrome (TAPS) is characterized by venous, arterial, or microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin has historically been the standard treatment. Apixaban is an oral factor Xa inhibitor anticoagulant that requires no dose a...

Descripción completa

Detalles Bibliográficos
Autores principales: Woller, Scott C., Stevens, Scott M., Kaplan, David, Wang, Tzu-Fei, Branch, D. Ware, Groat, Danielle, Wilson, Emily L., Armbruster, Brent, Aston, Valerie T., Lloyd, James F., Rondina, Matthew T., Elliott, C. Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941474/
https://www.ncbi.nlm.nih.gov/pubmed/34662890
http://dx.doi.org/10.1182/bloodadvances.2021005808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941474/
https://www.ncbi.nlm.nih.gov/pubmed/34662890
http://dx.doi.org/10.1182/bloodadvances.2021005808

Ejemplares similares